TEL AVIV, Israel and BETHESDA, Maryland, Feb. 16, 2021 /PRNewswire/
Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, has just released the final results of its in-vivo study evaluating the efficacy of the company’s proprietary drug candidate RCC-33 for the treatment of colorectal cancer in nude-mice. The final study results demonstrate a significant and robust inhibitory effect on tumor growth, as evidenced by a 33% reduction in tumor volume in mice exposed to RCC-33 in comparison with sham control mice (p ≤ 0.016).
Study design and results:
Both the experimental and the control groups were inoculated with human colorectal cancer cells. Daily doses of intraperitoneal (IP) delivery of RCC-33 or sham control were initiated on day 5. Differences in tumor volume between the two groups were first observed after 5 days of treatment (day 10). Previously published interim results showing a 27% reduction in tumor volume were recorded after 12 days of treatment (day 17), with p value ≤ 0.022. The study was concluded after 16 days of treatment (day 21) when a member of the control group reached a predetermined tumor size. Final results recorded a significant and robust 33% reduction in tumor volume in RCC-33 treated mice in comparison with the control group, p value ≤0.016.
Eyal Barad, Cannabics Pharmaceuticals’ Co-founder and CEO said: “The outlook of the oncology market puts this sector’s therapeutics sales forecast at $250 billion by 2024, according to a recent McKinsey report. While this is the market we ultimately have in sight, our initial penetration efforts with RCC-33 are focused on developing a colorectal cancer treatment catering to a $10 billion market with a ‘massive unmet need’, as articulated in the same McKinsey report”.
Gabriel Yariv, Cannabics Pharmaceuticals’ President and COO said: “Having successfully completed this in-vivo POC study, the company is now planning to finalize its product dossier preparation for a forthcoming submission to the FDA along with a request for a pre-IND meeting for RCC-33. We are paving the way with a potentially new treatment approach for colorectal cancer patients, one that could possibly have an important positive impact on a large group of patients, and we feel comfortable and look forward to bringing our scientific data before the regulatory authorities for review”.
Certain statements contained in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws. Such statements include but are not limited to statements identified by words such as “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “targets,” “projects” and similar expressions. The statements in this release are based upon the current beliefs and expectations of our Company’s management and are subject to significant risks and uncertainties. Actual results may differ from those outlined in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and regulation, potential litigation by or against us, any governmental review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission including, without limitation, our latest 10-Q Report filed January 14th, 2021. We undertake no duty to update any forward-looking statement or any information contained in this press release or other public disclosures at any time. Finally, the investing public is reminded that the only announcements or information about Cannabics Pharmaceuticals Inc., which are condoned by the Company, must emanate from the Company itself and bear our name as its source.